Navigation Links
Prismic Pharmaceuticals Acquires Scarista's Exclusive License to Amarin's Omega-3 Patents for CNS Disorders
Date:2/7/2012

SCOTTSDALE, Ariz., Feb. 7, 2012 /PRNewswire/ -- Prismic Pharmaceuticals, Inc., a Scottsdale, Arizona-based, emerging pharmaceutical company, today announced that it has completed the acquisition of the assets of Scarista Limited. In particular, Prismic has acquired Scarista's exclusive license from Amarin Neuroscience Limited, a wholly owned subsidiary of Amarin Corporation, to develop, market, and out-license products based on a portfolio of issued U.S. and foreign composition and use patents covering highly purified forms of Omega-3 fatty acids alone or in combination with other molecules for the treatment of disorders of the central nervous system (CNS). 

Commenting on this acquisition, Peter Moriarty, the Chairman and co-founder of the company, stated, "This is an important milestone in the development of Prismic Pharmaceuticals. Having gained access to the robust patents through the acquisition of Scarista, Prismic is planning to partner with one or more pharmaceutical companies in order to maximize the considerable commercial opportunity the patents offer in the CNS area."  

"There is already an established body of research and clinical experience indicating the therapeutic benefits and safety of highly purified forms of EPA and DHA for the treatment of cardiovascular disease. There is also similar data relating to their use in the treatment of a number of CNS disorders," Moriarty added. "Prismic, therefore, believes that any company licensing our IP will have the opportunity to bring patent-protected formulations to market relatively expeditiously." 

About Prismic Pharmaceuticals, Inc.

Prismic Pharmaceuticals, Inc., is a privately held pharmaceutical company focused on the development and marketing of novel prescription pharmaceuticals for psychiatric and neurodegenerative disorders, and prescription medical foods for the clinical dietary management of the metabolic processes associate
'/>"/>

SOURCE Prismic Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)...  Champions Oncology, Inc. (OTC: CSBR), engaged in the ... the development and use of oncology drugs, today announced ... 2015. Fourth Quarter and Recent Business Highlights: ... prior year period result , Procured a quarterly ... Joel Ackerman, Champions Oncology CEO, stated, "The end of ...
(Date:7/28/2015)... 28, 2015  Roche (SIX: RO, ROG; OTCQX: ... for Clinical Chemistry (AACC) 2015 Clinical Lab Expo ... and a unique educational initiative that demonstrates how ... value of the laboratory. The new ... empower laboratories and the people within them through ...
(Date:7/28/2015)... and HOUSTON, TX , July 28, 2015 ... EPIX ) is pleased to announce that it has received ... commence trading on the Toronto Stock Exchange (the "TSX"). The ... trading on Tuesday, July 28, 2015 under the trading symbol ... TSX Venture Exchange. About ESSA Pharma Inc. ...
Breaking Medicine Technology:Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 2Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 3Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 4Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 5Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 6Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 7Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 8Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 9Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 10Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 11Roche introduces LabLeaders educational initiative to help redefine the value of the laboratory at AACC 2015 Clinical Lab Expo 2Roche introduces LabLeaders educational initiative to help redefine the value of the laboratory at AACC 2015 Clinical Lab Expo 3Roche introduces LabLeaders educational initiative to help redefine the value of the laboratory at AACC 2015 Clinical Lab Expo 4ESSA Pharma Inc. to Commence Trading on the Toronto Stock Exchange 2ESSA Pharma Inc. to Commence Trading on the Toronto Stock Exchange 3
... Inc. (NASDAQ: ARNA ) today announced that Robert ... Vice President, Finance and Chief Financial Officer. Mr. Hoffman served ... before departing in March to work for a private biopharmaceutical ... been a key contributor to Arena," said Jack Lief, Arena,s ...
... 2011 / PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: ... commercializing products targeting the extracellular matrix , today ... 2011 Life Sciences Conference in New York. The presentation ... EDT (6:10 a.m. PDT). To listen to the live ...
Cached Medicine Technology:Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer 2Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer 3Halozyme Therapeutics to Present at the Wedbush 2011 Global Healthcare Conference on August 17 2
(Date:7/28/2015)... Boston, MA (PRWEB) , ... July 28, 2015 , ... ... developing cancer. One reason is that cancer, heart attack, and stroke are treatable, but ... One thing individuals can do is to take part in a clinical trial, reports ...
(Date:7/28/2015)... ... July 28, 2015 , ... The ... Attack, Sudden Death, or Angina), many of whom are missed by conventional evaluation ... individuals with active yet undetected sub-clinical disease, who are at risk of experiencing ...
(Date:7/28/2015)... ... July 28, 2015 , ... For more than two ... based its selection process on the foundation of peer nominations. Physicians nominate other ... any area of medicine and in any part of the country. Physicians cannot ...
(Date:7/28/2015)... ... July 28, 2015 , ... One ... including Runner’s World Magazine, is plantar fasciitis . Zensah, the Miami-based compression ... Designed by a professional athletic trainer, the Zensah Ankle Support’s primary benefits include ...
(Date:7/28/2015)... ... , ... Nurses across all settings increasingly provide care to people with mental ... mental health services (SAMHSA, 2013) and the implementation of the Affordable Care Act is ... the largest workforces who provide care to persons with mental health disorders. Providing this ...
Breaking Medicine News(10 mins):Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3Health News:Utility of a novel coronary artery disease biomarker algorithm in modifying physician adherence to guideline therapy presented at 20th World Congress on Heart Disease 2Health News:Fort Myers Plastic Surgeon Recognized as One of the America’s “Top Doctors®” by Prestigious Castle Connolly Medical Ltd. for 5 Years in a Row 2Health News:Fort Myers Plastic Surgeon Recognized as One of the America’s “Top Doctors®” by Prestigious Castle Connolly Medical Ltd. for 5 Years in a Row 3Health News:Zensah Releases Compression Sleeve To Relieve Ankle Pain and Plantar Fasciitis 2Health News:American Psychiatric Nurses Association Transitions in Practice Certificate Program to Improve Mental Health Care Through Continuing Nursing Education 2Health News:American Psychiatric Nurses Association Transitions in Practice Certificate Program to Improve Mental Health Care Through Continuing Nursing Education 3Health News:American Psychiatric Nurses Association Transitions in Practice Certificate Program to Improve Mental Health Care Through Continuing Nursing Education 4
... being circulated in South Asia for various ailments like malaria, ... a British doctor in Laotian capital, Vientiane, the drugs have ... find out. ,World Health Organization states that majority ... been treated with the original drug. They also add that ...
... the makers of ADHD drugs to indicate the contra indications ... cardiovascular risks. ,Dr. Steven Galson, director of the ... these drugs are immensely useful in treating patients with ADHD, ... He also said that FDA is working in tandem ...
... of your wedding celebration. The world-renowned research and care center ... save lives of cancer patients. Couples getting married are encouraged ... Jimmy Fund. Dana-Farber treats both children and adults, and is ... ,A package of 10 table cards, gift cards, or ...
... about that shared experience are likely more satisfied with ... of experience to draw on, according to research by ... ,The study, conducted by Doris G. Bazzini and three ... issue of the journal Motivation and Emotion. ...
... Mukesh Haikerwal, today congratulated the Victorian Government on introducing ... child carers are trained in handling potentially deadly severe ... anaphylaxis program to be implemented nationally. ... to protect the children who suffer from severe allergies, ...
... who become impotent after prostate cancer surgery may find reprieve ... penis,// which assists in restoring the lost erectile function, according ... came to light after a study of nearly 44 patient ... function, following its loss after treatment for prostate cancer. ...
Cached Medicine News:Health News:Researcher Studies Benefits of Reminiscing About Laughter 2Health News:National Plan Needed for Severe Allergy Kids 2
Immuno-turbidimetric assay for Free Protein Sby STA© Analyzers. Suspension of microparticles coated with monoclonal antibodies to Free Protein S....
Colorimetric Assay of Unfractionated and Low Molecular Weight Heparins by STA© Analyzers. Lyophilized, patent-pending chromogenic substate, CBS 52.44 of ~4.2 moles/vial and bovine factor Xa ~1.1...
Substrate Plasma for Factor VII Assay by STA© Analyzers. Freeze-dried human plasma from which factor VII has been removed by selective immuno-adsorption....
Substrate Plasma for Factor IX Assay by STA© Analyzers. Freeze-dried human plasma from which factor IX has been removed by selective immuno-adsorption....
Medicine Products: